You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黄医药去年收入2.27亿美元 升11.27%
阿思达克 03-05 18:12
和黄医药(HCM.US)公布,去年收入2.27亿美元(下同),按年升11.27%,期内应占净亏损扩大至1.257亿元,2019年同期录1.06亿元净亏损。

其中肿瘤及免疫业务去年实际综合收入3,020万美元,而明年综合收入指引为1.1-1.3亿美元;受益於获纳入2020年中国国家医保药品目录,爱优特去年市场销售额升91%至3,370万美元;苏泰达於1月中旬获批於後3周在中国上市,上市後首两月未经审计销售额为490万美元。

另外,公司计划在股东周年大会上提呈易名「HUTCHMED (China) Limited和黄医药(中国)有限公司」。(el/a) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account